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Editorial on the Research Topic
New Horizons in Health-Promoting Technologies: From Development to Rational Use
This Research Topic covers 30 articles focusing on recent advancements related to the balance in
innovation technology and the rational use of medicine for better decision making.
Independent drug information comes from publications with no conflicts of interest, performed
by transparent and robust methods that validate the results that can subsequently be used to
improve health outcomes. The publication of studies of high methodological quality helps to
identify evidence about the benefits of medicines and technologies that are widely used as well as for
those that show substantial variation in their use but without improvement in health outcomes. No
less important are the findings that demonstrate which technologies that have proven to be
ineffective or have harmful effects, which continue to be used often driven by hype, hope, lack of
national guidance, or other pressures including financial pressures. We have seen this with the
considerable hype and misinformation surrounding the use of hydroxychloroquine in the treatment
of patients with COVID-19.
In a current scenario of limited financial resources, health managers are under pressure, which
requires greater efficiency in the use of public money. They need consistent and substantiated
information about the benefits and harm of health technologies and their impact on patients and
health services to guide future decision making. This Research Topic points out studies that can
contribute to this theme, having as a main focus the adequate and rational use of a medicine and
other technologies. Rational use of medicine occurs when patients receive the appropriate medicines
in doses that meet their own individual requirements, for an adequate period of time, and at the
lowest cost both to them and their community (WHO, 2004).
Inappropriate use of medicines can be costly and extremely harmful (related illness and deaths),
both to the individual and the population as a whole (Holloway and Van Dijk, 2011). Few healthcare
systems presently control the inappropriate use of medicines, which in some is due to a lack of
consciousness of the size of the problem and its economic and health burden. In others, decision-
makers often lack knowledge of themost cost-effective ways tomanage this important problem (Lima
et al., 2017) or have a reluctance to instigate demand-side measures to improve appropriate use
through pressures from key stakeholder groups (Lopes et al., 2010). Particularly, challenges and
barriers to be overcome in low- andmiddle-income countries are still considerable (Salas et al., 2020).in.org August 2020 | Volume 11 | Article 11801
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context of those consideredessential, is a topic that cancontribute to
the irrational use of medicines. Acosta et al. address this issue
through a scoping review in which the authors identified an
appreciable number of countries that are introducing legislative
actions to address shortages of medicines and discuss interest in
international cooperation for their prevention andways to facilitate
actions that provide a timely response.
The responsible use of medicines implies that existing activities,
capacities, resources, and key stakeholders are aligned to ensure the
rational use of medicines (WHO, 2012). Rational use, including
issues of adherence to medicines, is enhanced by the instigation of
universal healthcare including the continual availability of a key list
of essential medicines (Yamauti et al., 2015; Araujo et al., 2016;
Yamauti et al., 2017). This is important particularly in low-income
countries where the cost of medicines can account for up to 60% or
so of total healthcare expenditure, much of which is out of pocket
(Cameron et al., 2009) and should be addressed as part of
Sustainable Development Goals.
Interventions, including effective drug monitoring and
regulations, and encouraging rational use, have been well
described in studies that have addressed, among others, the
translation of knowledge through a brief political and deliberative
discourse (deAraújo et al.; Fulone et al.). In addition, aspects related
to the challenges and impact of control policies were addressed in
the study by Ranabhat et al. Some authors have shown that when
there is a lack of effective drug control andmonitoring, either due to
wrong selection of essential drugs for reimbursement or lack of
demand-side measures (Godman et al., 2014; Fulone et al., 2016;
Osorio-De-Castro et al., 2018) or lack of adherence of official
guidelines, health and expenditures (Silveira et al., 2014; De
Camargo et al., 2016) may be compromised.
It is worth mentioning that in this scenario, in addition to
translating knowledge and control policies (Wettermark et al.,
2009), the participation of health professionals in a responsible
way to expand access and the responsible use of the medicines,
mainly in the vulnerable population, assumes significant
relevance (Soler and Barreto; Silva et al.). Observational studies
carried out with health professionals showed that clinical
practice also needs to be reviewed and improved, suggesting
significant gaps in the knowledge of appropriate prescriptions
(Benko et al.; Fadare et al.).
A good decision should include society’s values, the interests of
those potentially involved, and an appreciation of local policies.
There is widespread recognition of the need to use information
more effectively to inform public health policies, programs, and
administrative decisions. To consistently contribute to this theme,
some authors of this Research Topic have also included studies
that provided important tools to improve health decision-making
(Ali et al.; Barcelos et al.) to assist in clinical practice (Félix et al.;
Motter et al.; Amodeo et al.) and the quality of the methods used in
primary studies (Ali et al.).
New technologies are registered based on controlled and
randomized clinical trials, in which, in most cases, they fail to
capture important safety results that only appear in real-life
studies (Lopes et al., 2014; Fulone et al., 2018; De Carmago et al.,Frontiers in Pharmacology | www.frontiersin.org 22019). In addition, in the case of new cancer medicines, often
licensed on the basis of limited information, which can cause
concern and wasted resources (Pontes et al., 2020).
This Research Topic brings together interesting features specified
for secondary (Andrade et al.; Lee et al.; Liu et al.; Mellone et al.;
Mezones-Holguin et al.) and primary studies (Cavalcanti et al.;
Gomes et al.) of technologies already used in several countries.
However, doubts related to their effectiveness and safety still point
out that they need to be better studied in different contexts. Part of
the continued growth in health spending is attributable to the
increasing production of new technologies and changes in the
population’s epidemiological profile. Studies that indicate whether
a technology is cost-effective contribute to adjustments in health
policies adopted. The cost-effectiveness study developed by Vecoso
et al. showed that the chemoprophylaxis of influenza A (H1N1) is
cost-saving in theBrazilianhealth systemcontext.On theotherhand,
a number of Brazilian studies have cast doubt on the inclusion of
insulin glargine within public health systems in Brazil given
appreciable higher prices that existed versus NPH insulins (Caires
De Souza et al., 2014; Marra et al., 2016).
In addition, the rapid emergence of high-priced innovations is
another major challenge faced by decision-makers. In order to
respond, the identification of future innovations and trends should
be carried out in a comprehensive, systematic, and sustainable
manner so that policymakers and other interested parties can
respond appropriately and improve the managed entry of new
medicines starting with horizon scanning and budgeting activities,
followed by funding and reimbursement decisions and
subsequently post launch patient-level studies (Malmström et al.,
2013; Godman et al., 2015). The comprehensive model in Sweden
provides an exemplar to others (Eriksson et al., 2017; Eriksson et al.,
2019). Authors have also discussed important aspects related to
gaps in gene therapy assessment (Jolly et al.) and new technologies
to combat multidrug-resistant bacteria (Lima et al.).
To improve the input from new developing technologies, this
Research Topic also brought together interesting studies that show
preliminary experiments, in “in vitro” phase, using, among others,
biopharmaceutical techniques that modify the pharmaceutical
form currently commercialized to increase the permeation of
molecules in the skin (Vigato et al.) or through the encapsulation
of antibiotics that result in increased antimicrobial effectiveness
(Scriboni et al.) addressing concerns with the lack of new antibiotics
being developed to address rising resistance concerns. In addition,
discussions concerning combined delivery systems based on
nanostructures to administer drugs by the oral cavity (Feitosa
et al.). Tests with promising agents to treat diabetes (Muñoz-
Talavera et al.) or osteoporosis have also been presented (Hou
et al.). We will be following up their development.AUTHOR CONTRIBUTIONS
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Estado de São Paulo. Rev. Saúde Públ. 44, 620–628. doi: 10.1590/S0034-
89102010000400005
Lopes, L. C., Silveira, M. S., De Camargo, M. C., De Camargo, I. A., Luz, T. C.,
Osorio-De-Castro, C. G., et al. (2014). Patient reports of the frequency and
severity of adverse reactions associated with biological agents prescribed forFrontiers in Pharmacology | www.frontiersin.org 3psoriasis in Brazil. Expert Opin. Drug Saf. 13, 1155–1163. doi: 10.1517/
14740338.2014.942219
Malmström, R. E., Godman, B. B., Diogene, E., Baumgärtel, C., Bennie, M., Bishop, I.,
et al. (2013). Dabigatran - a case history demonstrating the need for comprehensive
approaches to optimize the use of new drugs. Front. Pharmacol. 4, 39. doi: 10.3389/
fphar.2013.00039
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